We work to protect patients against the burden of influenza, respiratory syncytial virus (RSV) and bacterial infections, particularly those resistant to current antibiotics.

With a rich heritage and a research and development focus on specific aspects of neurodegenerative diseases, analgesia and psychiatry, AstraZeneca continues to push the boundaries of science in neuroscience in collaboration with other innovative partners across industry and academia.

Expanding the reach of our medicines to address these inflammatory illnesses in which elevated eosinophils are a direct cause or are thought to play a critical role.